Bioventus Reports Second Quarter Financial Results
Bioventus has announced strong financial results for the second quarter of 2024, showing significant growth in revenue and profitability, particularly in its Pain Treatments and Surgical Solutions segments. Despite reporting a net loss due to an impairment charge and litigation costs, the company increased its adjusted EBITDA and raised its full-year financial guidance. Key strategic initiatives include the potential divestiture of its Advanced Rehabilitation Business and the FDA clearance of OSTEOAMP Cannula, aiming to enhance shareholder value and focus on core strengths.
Anderson Financial Strategies LLC Invests $901,000 in Bioventus Inc. $BVS
Anderson Financial Strategies LLC has acquired a new stake of 134,720 shares in Bioventus Inc. (NYSE:BVS) during the third quarter, valued at approximately $901,000. This investment represents about 0.16% ownership of Bioventus and constitutes roughly 0.5% of Anderson Financial Strategies LLC's portfolio. Meanwhile, two directors, Guy P. Nohra and Michelle Mcmurry-Heath, recently reduced their holdings in Bioventus through stock sales.
Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year
Institutional investors own 36% of Bioventus Inc. (NASDAQ:BVS), making the stock vulnerable to their trading decisions. The top 5 shareholders collectively own 52% of the company, with Essex Woodlands Management, Juniper Investment Company, and Smith & Nephew plc being the largest. Despite a 13% loss over the past year, a recent US$55m market cap gain might be welcomed by these institutional owners.
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. The firm encourages current Bioventus stockholders, especially long-term shareholders, to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company oversight and enhance shareholder value.
Bioventus appoints Ajay Dhankhar to board as Class II director
Bioventus Inc. has appointed Ajay Dhankhar, PhD, as a Class II director to its board, effective Thursday. Dr. Dhankhar, currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc, will serve until the 2026 annual meeting of stockholders. This appointment aligns with a Stockholders Agreement allowing Smith & Nephew to designate directors, with Dr. Dhankhar being their second designee.
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors
Bioventus Inc. announced the appointment of Ajay Dhankhar, PhD, to its Board of Directors as a Class II director, effective November 14, 2025. Dr. Dhankhar will serve until the 2026 annual meeting of stockholders and brings experience as Chief Corporate Development & Strategy Officer at Smith & Nephew plc. This appointment was officially filed with the SEC on November 17, 2025.
Bioventus Appoints Ajay Dhankhar as New Director
Bioventus Inc. (BVS) has appointed Ajay Dhankhar, PhD, as a Class II director, effective November 14, 2025. This appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors. Dr. Dhankhar will not receive compensation for his role.
Bioventus (BVS): $17.3M One-Time Loss Raises Questions About Quality of New Profitability
Bioventus (BVS) recently returned to profitability despite a one-time loss of $17.3 million, raising questions about the quality of these new earnings. The company faces significant debt, which poses a threat to future R&D and market responsiveness. Despite trading at a steep discount to fair value, its high P/E ratio and debt burden warrant caution among investors.
BVS Stock Quote Price and Forecast
This article provides a detailed financial overview and forecast for Bioventus, Inc. (BVS), including its current stock price, recent performance, key financial metrics, and a compilation of recent news and analyst ratings. It highlights the company's operational segments and its position within the medical technology sector.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Form 10-Q report for the third quarter of 2025, highlighting stable financial performance with improvements in operating income and a positive net income turnaround. The company's U.S. segment remains the primary revenue driver, particularly in Pain Treatments and Surgical Solutions, which are also targeted for future growth alongside international expansion.
Head-To-Head Survey: Bioventus (NASDAQ:BVS) & Shoulder Innovations (NYSE:SI)
This article provides a head-to-head comparison of Bioventus (NASDAQ:BVS) and Shoulder Innovations (NYSE:SI), examining their institutional ownership, insider ownership, earnings, valuation, analyst recommendations, and profitability. The analysis concludes that Bioventus outperforms Shoulder Innovations on 7 out of 12 factors discussed. Detailed company profiles are also included.
Bioventus Secures Dual FDA Clearance for Revolutionary Non-Opioid Pain Management Technology
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new peripheral nerve stimulation (PNS) products, TalisMann™ and StimTrial™, for chronic pain management. These clearances position Bioventus to tap into a PNS market projected to exceed $500 million by 2029 with over 20% annual growth. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026, offering non-opioid, minimally invasive therapies.
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Bioventus reported strong financial results for the fourth quarter and full year 2024, with worldwide revenue increasing by 13.5% and 11.9% respectively, driven by growth in Pain Treatments and Surgical Solutions. The company also announced an increase in Adjusted EBITDA and provided optimistic financial guidance for 2025, anticipating continued revenue growth and operating margin expansion. These results follow strategic moves including the divestiture of its Advanced Rehabilitation Business and debt reduction.
Bioventus CFO Mark Leonard sells $113,018 in stock
Bioventus CFO Mark Leonard recently sold 10,733 shares of the company's Class A common stock, valued at $113,018. The company has seen its stock surge over 90% in the last six months and is expected to become profitable this year. Bioventus also reported strong third-quarter 2024 results, including a 15% year-over-year revenue increase and raised full-year guidance, highlighting its strong financial health and strategic growth initiatives.
Bioventus SVP Katrina Church sells $26,693 in stock By Investing.com
Katrina J. Church, SVP and Chief Compliance Officer at Bioventus Inc. (NASDAQ: BVS), sold 2,535 shares of company stock for $26,693 to cover taxes on vested restricted stock units. This transaction occurred after Bioventus saw a 102% gain over the past year and raised its full-year revenue guidance to between $562 million and $567 million due to strong Q3 growth. The company reported a 15% year-over-year increase in Q3 revenue to $139 million, driven by surgical solutions and the HA business.
Shareholder lawsuit ends with $15 million settlement
A federal judge has approved a $15.25 million settlement in a shareholder lawsuit against Durham-based Bioventus. The lawsuit alleged that the company misled shareholders regarding its financial performance. This settlement concludes the legal claims against the company.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Q3 2024 Form 10-Q report, detailing significant financial growth with net sales reaching $138.964 million for the quarter and $419.638 million year-to-date, marking an improvement in net loss compared to the prior year. The report highlights strategic initiatives like the divestiture of non-core assets to improve liquidity and reduce debt, new product launches, and regulatory approvals. However, the company also acknowledges challenges such as impairment charges related to divestitures, regulatory compliance costs, and potential dilution of ownership interests.
Bioventus reaches $15.25 million settlement in securities lawsuit
Bioventus Inc. has agreed to a $15.25 million settlement in a securities class action lawsuit, resolving claims related to rebate practices, financial prospects, and internal controls. While the settlement requires court approval and does not admit liability, it aims to conclude litigation dating back to January 2023. This development occurs as Bioventus reports strong financial performance in Q1 2024 and significant corporate governance changes.
Durham company agrees to $15 million settlement in shareholder lawsuit
A Durham company, Bioventus, has agreed to a $15 million settlement in a shareholder lawsuit. The lawsuit alleged that the company misstated its financial results, leading to an artificially inflated stock price. This settlement addresses claims related to these financial misrepresentations.
Bioventus Deserves A Look After A Beat And Raise Report
Bioventus Inc. reported strong financial results for the first quarter of 2024, exceeding analyst expectations for revenue and significantly reducing its net loss. Based on this performance, the company has raised its full-year 2024 revenue and non-GAAP EPS forecasts, indicating confidence in continued growth. The stock saw a significant increase following the report.
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Bioventus Inc. announced the issuance of inducement equity awards to Robert Claypoole in connection with his appointment as President, Chief Executive Officer, and Principle Executive Officer. The awards consist of 375,000 restricted share units and options to purchase 850,000 shares of the Company’s Class A common stock. These awards will vest in four equal installments over four years, subject to his continued employment.
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint filed in January 2023. The investigation concerns potential breaches of fiduciary duties by Bioventus's board of directors, stemming from alleged misleading statements in IPO documents regarding liquidity issues, unsustainable rebate practices, and inadequate internal controls. These issues led to significant stock price declines and investor losses.
Bioventus Announces CEO Leadership Change
Bioventus Inc. announced that Ken M. Reali has stepped down as CEO and board member. The board has initiated a search for a permanent CEO and appointed Anthony Bihl as interim CEO. Bihl previously served as CEO of Bioventus LLC and aims to stabilize the company and improve execution.
Bioventus Announces CEO Leadership Change
Bioventus Inc. announced that Ken M. Reali has stepped down as CEO and board member. Anthony Bihl, former CEO of Bioventus LLC, has been appointed interim CEO while the board searches for a permanent successor. The company aims to address performance, unlock long-term value, and enhance shareholder value under Bihl's interim leadership.
BIOVENTUS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bioventus Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announced a class action lawsuit against Bioventus Inc. (NASDAQ: BVS) for investors who purchased securities around its February 11, 2021 IPO. The lawsuit alleges that Bioventus's offering documents contained misleading statements and failed to disclose significant liquidity issues, unsustainable rebate practices, and deficient internal controls, which led to a substantial drop in stock price. Investors have until March 13, 2023, to apply to be a lead plaintiff.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS
Rosen Law Firm is encouraging investors of Bioventus Inc. (NASDAQ: BVS) to join a securities class action lawsuit before the March 13, 2023 lead plaintiff deadline. The lawsuit alleges that Bioventus made false and misleading statements in its offering documents and during the Class Period, particularly regarding liquidity issues, unsustainable rebate practices, and deficient financial controls, leading to investor damages. Investors who purchased Bioventus securities during the specified period may be entitled to compensation.
ROSEN, A LEADING LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BVS
Rosen Law Firm is encouraging investors of Bioventus Inc. to secure legal counsel before the March 13, 2023 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Bioventus made false and misleading statements in its offering documents and during the Class Period (February 11, 2021, to November 21, 2022) regarding its liquidity, rebate practices, and financial reporting. Investors who purchased Bioventus securities during this period may be entitled to compensation.
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz is reminding investors of upcoming deadlines to file lead plaintiff motions in class action lawsuits against ESS Tech, Inc. (GWH), Bioventus Inc. (BVS), Y-mAbs Therapeutics, Inc. (YMAB), and Fate Therapeutics, Inc. (FATE). The lawsuits allege that these companies made materially false and misleading statements to investors. Shareholders who suffered losses are encouraged to contact the firm to discuss their legal rights.
DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices
The Law Offices of Frank R. Cruz issued a deadline alert for class action lawsuits against Southwest Airlines Co. (LUV), ESS Tech, Inc. (GWH), Bioventus Inc. (BVS), and Y-mAbs Therapeutics, Inc. (YMAB). Investors in these companies have until March 13 or March 20, 2023, to file a lead plaintiff motion. The lawsuits allege that these companies made materially false and/or misleading statements and failed to disclose critical information regarding their business operations and prospects.
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION
Bernstein Liebhard LLP has reminded investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit against Bioventus Inc. (NASDAQ: BVS). The lawsuit alleges that Bioventus made false and misleading statements regarding its liquidity, rebate practices, and financial prospects during its IPO and subsequent Class Period, leading to significant stock price drops. Investors who purchased Bioventus securities between February 11, 2021, and November 21, 2022, are encouraged to contact the firm to discuss their rights.
Lowey Dannenberg Notifies Bioventus Inc. (NASDAQ: BVS) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
Lowey Dannenberg P.C. has filed a class action lawsuit against Bioventus Inc. (NASDAQ: BVS) on behalf of investors who purchased its stock relating to its February 2021 IPO and/or between February 11, 2021, and November 21, 2022. The lawsuit alleges that Bioventus made false and misleading statements regarding its business, operations, and compliance, failing to disclose liquidity issues, unsustainable rebate practices, and deficient disclosure controls. Investors who suffered losses are encouraged to contact Lowey Dannenberg before the March 13, 2023 lead plaintiff deadline.
Bioventus Investor Alert
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) following a significant stock price drop. The investigation encourages investors who lost over $50,000 to contact the firm after Bioventus was unable to file its quarterly report and disclosed inadequate internal controls, leading to an 84.85% decline from its IPO price.
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Bioventus Inc. Investors to Inquire About Securities Class Action Investigation – BVS
Rosen Law Firm has initiated an investigation into potential securities claims against Bioventus Inc. (NASDAQ: BVS) following allegations of materially misleading business information. If you purchased Bioventus securities, you may be entitled to compensation through a class action lawsuit. This investigation follows Bioventus's announcement that it could not timely file its quarterly report due to a review for a potential non-cash impairment charge and issues with rebate claims, leading to a significant drop in its stock price.
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm is investigating Bioventus Inc (NASDAQ: BVS) on behalf of investors who lost money. This follows Bioventus's announcement of an extension for its quarterly report due to a contested invoice and inadequate internal controls, which will likely negatively impact its Q3 2022 financial results and ability to meet financial obligations. Investors are encouraged to contact the firm to discuss their legal rights and potentially recover losses.
Bioventus Inc. Shareholder News: Johnson Fistel Encourages
Johnson Fistel, LLP is investigating Bioventus Inc. (NASDAQ: BVS) for potential securities law violations after the company announced it could not timely file its quarterly report due to a potential non-cash impairment charge of $185 million to $205 million and issues with rebate claims. This news follows a significant drop in Bioventus' stock price, which closed at $1.90 on November 18, 2022, after an IPO price of $13.00 per share in February 2021. The firm is encouraging shareholders who have suffered losses to contact them regarding a class action investigation.
The $518M deal for Bioventus to buy Misonix is now complete
Bioventus Inc. has completed its acquisition of Misonix, Inc. in a cash and stock transaction valued at $518 million. This acquisition aligns with Bioventus' mission of delivering innovations for active healing and is expected to accelerate revenue growth by leveraging existing infrastructure and creating significant commercial synergies. Bioventus also recently made a $50 million escrow payment to advance with the acquisition of CartiHeal Ltd.
Misonix merges with Bioventus
Jones Day represented Misonix, Inc. in its acquisition by Bioventus Inc. Misonix stockholders received either cash or Bioventus common stock for their shares. Two Misonix board members joined the Bioventus Board of Directors post-merger.
MISONIX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MSON and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has launched an investigation into Misonix, Inc.'s proposed $518 million merger with Bioventus Inc., announced on July 29, 2021. The firm is concerned that the board of directors may have overseen an unfair process and agreed to an inadequate merger agreement, offering stockholders a choice of $28 in cash or 1.6839 shares of Bioventus common stock per Misonix share. They encourage Misonix shareholders to contact the firm to learn about their legal rights and remedies.
Misonix Reports Preliminary Fiscal 2021 Fourth Quarter and Full Year Revenue Results
Misonix reported strong preliminary unaudited fiscal 2021 fourth quarter and full year revenue results, with total revenue increasing by 43.5% and 18.5% year-over-year, respectively. Concurrently, the company announced a definitive merger agreement to be acquired by Bioventus for approximately $518 million in a cash-and-stock transaction. This acquisition is expected to create a leading restorative medicine and orthopedics company with significant growth opportunities.
Bioventus Appoints Mary Kay Ladone to Board of Directors
Bioventus Inc. has appointed Mary Kay Ladone to its Board of Directors, effective July 15, 2021. Ladone, an experienced healthcare executive, will also serve on the Board’s Audit and Risk Committee and Compensation Committee. Her extensive background in finance, strategic planning, business development, and investor relations is expected to be invaluable to Bioventus's growth acceleration strategies.
Bioventus Acquires Bioness, Inc.
Bioventus Inc. has acquired Bioness, Inc. for $45 million upfront and up to $65 million in contingent consideration, aiming to expand its portfolio in neuromodulation and rehabilitation medical devices. This acquisition is expected to be accretive to Bioventus' revenue and positively contribute to net income by the end of the first year post-close. Bioness generated approximately $40 million in revenue in 2020 and its products address a total addressable market estimated at over $8 billion.
Latham & Watkins Advises Bioventus in its Initial Public Offering
Latham & Watkins LLP advised Bioventus Inc. on its initial public offering of 8 million shares of Class A common stock at US$13 per share, totaling approximately US$104 million. Bioventus's Class A common stock is now trading on the Nasdaq Global Select Market under the symbol "BVS." A bicoastal Latham & Watkins team provided comprehensive legal advice across various specializations for this transaction.
